자궁내막증 : 시장 전망, 역학, 경쟁 구도, 시장 예측 보고서(2025-2035년)

Endometriosis Market Outlook

Thelansis's "Endometriosis Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2025 To 2035" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Endometriosis treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Endometriosis Overview

Endometriosis is a chronic, estrogen-dependent, systemic inflammatory disease characterized by the presence of endometrial-like tissue outside the uterine cavity. These ectopic lesions most commonly localize to the pelvic peritoneum, ovaries, and uterosacral ligaments, and are classified into three major phenotypes: superficial peritoneal endometriosis, ovarian endometriomas, and deep infiltrating endometriosis (DIE), which can involve organs such as the bowel and bladder. The disease is driven by cyclic, estrogen-mediated activity of ectopic tissue, leading to recurrent bleeding, chronic inflammation, fibrosis, and adhesion formation. Clinically, this manifests as severe chronic pelvic pain, dysmenorrhea, dyspareunia, and infertility, significantly impairing quality of life. Notably, disease severity does not consistently correlate with staging systems such as the ASRM classification, prompting a shift toward symptom-driven and imaging-supported diagnosis.

There is currently no definitive cure, and management is centered on long-term symptom control. Treatment approaches include surgical intervention for lesion excision and hormonal therapies aimed at suppressing estrogen production, such as progestins and GnRH antagonists (e.g., elagolix, relugolix). Despite available options, recurrence and suboptimal symptom control remain common, underscoring persistent unmet need.

Key Highlights

• In the US, symptomatic cases are projected to increase from 4.41M in 2025 to 4.72M by 2035, reflecting steady growth (0.7% CAGR) driven by improved awareness and diagnosis.
• The disease is associated with substantial diagnostic delays and heterogeneous presentation, complicating effective disease management.
• Lack of curative therapies and high recurrence rates highlight a significant unmet need for more durable and targeted treatment options.

Market Overview

• The Germany endometriosis market is projected to grow from $124M in 2025 to $414M by 2035, reflecting strong double-digit growth driven by uptake of novel hormonal therapies.
• Market expansion is supported by:
• Increasing adoption of oral GnRH antagonists and advanced hormonal treatments
• Improved diagnosis and treatment rates
• Despite moderate patient growth, market value is driven by chronic treatment duration and premium-priced therapies.
• Future growth will depend on the development of disease-modifying therapies that provide sustained symptom relief and reduce recurrence rates.

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support
• As per Thelansis's policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2025-2035)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market's trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country

Companies Mentioned

• Kissei Pharmaceutical Co., Ltd.
• Hope Medicine (Nanjing) Co., Ltd.
• Organon and Co
• Gesynta Pharma AB
• Nanjing Chia-tai Tianqing Pharmaceutical
• AbbVie
• Sumitomo Pharma Switzerland GmbH
• Changchun GeneScience Pharmaceutical Co., Ltd.
• Jiangsu HengRui Medicine Co., Ltd.

Table of Contents

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risks, etc.

2. Disease Context

• Disease definition, classification, etiology and pathophysiology, drug targets, etc.

3. Epidemiology

• Key takeaways
• Incidence / Prevalence
• Diagnosed and Drug-Treated populations
• Comorbidities
• Other relevant patient segments

4. Market Size and Forecast

• Key takeaways
• Market drivers and constraints
• Drug-class specific trends
• Country-specific trends

5. Competitive Landscape

• Current therapies
• Key takeaways
• Dx and Tx journey/algorithm
• Key current therapies - profiles and KOL insights
• Emerging therapies
• Key takeaways
• Notable late-phase emerging therapies - profiles, launch expectations, KOL insights
• Notable early-phase pipeline

6. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)